HIGHLAND CAPITAL PARTNERS
Upcoming SlideShare
Loading in...5
×
 

HIGHLAND CAPITAL PARTNERS

on

  • 610 views

 

Statistics

Views

Total Views
610
Slideshare-icon Views on SlideShare
610
Embed Views
0

Actions

Likes
0
Downloads
5
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    HIGHLAND CAPITAL PARTNERS HIGHLAND CAPITAL PARTNERS Presentation Transcript

    • THE ROLE OF THE PRINCIPAL INVESTIGATOR Creating and Funding Start-Ups: A Venture Capital Perspective NOUBAR AFEYAN FLAGSHIP VENTURES MAY 2007
    • My Background » Ph.D. in Biochemical Engineering from MIT in 1987 » 20 year career in Entrepreneurship » Last 7 years also in Venture Capital » Senior Lecturer at MIT Sloan School » >30 papers and > 25 patents » Focused on creating “Return on Innovation” 2
    • Entrepreneurial Experiences Past (1987 - 1999) • PerSeptive Biosystems Instruments for Biotechnology • ChemGenics Pharma Genomics & Drug Discovery • Antigenics Cancer Vaccines • Exact Science Cancer Diagnostics • Color Kinetics Solid State Lights (LEDs) • Celera Genomics Information & Services for Discovery 3
    • Entrepreneurial Experiences Past (1987 - 1999) • PerSeptive Biosystems Instruments for Biotechnology • ChemGenics Pharma Genomics & Drug Discovery • Antigenics Cancer Vaccines • Exact Science Cancer Diagnostics • Color Kinetics Solid State Lights (LEDs) • Celera Genomics Information & Services for Discovery Vibrant Outstanding Markets People Intellectual Property 4
    • Flagship Ventures » Formed in 2000 to finance entrepreneurial innovation » $700M under management » Primary focus on Life Science innovations » Experienced partnership team of 8 Partners and Principals with deep domain expertise and extensive networks » Balanced portfolio exposure across therapeutics, diagnostic tools and platform technologies » Unique Venture Creation and Seed Investment programs 5
    • Entrepreneurial Experiences Past (1987 - 1999) • PerSeptive Biosystems Instruments for Biotechnology • ChemGenics Pharma Genomics & Drug Discovery • Antigenics Cancer Vaccines • Exact Science Cancer Diagnostics • Color Kinetics Solid State Lights (LEDs) • Celera Genomics Information & Services for Discovery Present (2000 - ) Flagship Ventures • BG Medicine Systems Biology for Drug Development • Affinnova On-line, Consumer-led Product Design On- Consumer- • Genstruct Computational Systems Biology • Adnexus Therapeutics Engineered Biotherapeutics • Epitome Biosystems Protein measurement biochips • Helicos BioSciences Single Molecule DNA Sequencing • Ensemble Discovery DNA-Programmed Chemistry DNA- • Codon Devices Synthetic Biology • LS9 Biofuels • T2Bio Nanoparticle-based diagnostics Nanoparticle- 6
    • Finding a Profit Zone Technically Desirable to possible large or growing market Can be produced/ Can be delivered protected at a profit 7
    • Case Studies
    • CODON DEVICES » Harvard, Duke, and University of Wisconsin – equity ownership, license fees, and royalties » MIT – annual license fees and FOUNDERS royalties George Church, HMS Joe Jacobson & Drew Endy, MIT » Platform using sophisticated Jay Keasling, UC Berkeley informatics and robotics to synthesize DNA more rapidly, VC INVESTORS accurately and cost-effectively Flagship Ventures, Highland than current technology Capital Partners, Khosla Ventures, KPCB, Alloy Ventures » Creating a paradigm shift in “constructive biology” AMOUNT RAISED $33 million (over 2 rounds) » Founders are leaders of the synthetic biology field 9
    • HELICOS BIOSCIENCES » Formed after discussions with Prof. Steven Quake (Caltech/Stanford) and Prof. Eric Lander (MIT/Harvard/Broad) FOUNDERS » Licensed technology from Caltech Steve Quake, Caltech/Stanford and several additional universities Stan Lapidus » Single Molecule Analysis for VC INVESTORS sequencing, polymorphism, gene Atlas Ventures, Flagship expression, methylation, etc. Ventures, Highland Capital Partners, MPM Capital, Versant » Launching Heliscope late in 2007 Ventures AMOUNT RAISED » Expanding applications while $66.9 million (over 2 rounds) dramatically lowering cost 10
    • HELICOS BIOSCIENCES Proceedings of the National Academy of Science: April 1, 2003 11
    • Venture Opportunities in 2007 and beyond Untreated diseases represent >50% of health care costs; most drugs work in few patients Drug development process involves very high attrition in addition to high cost and duration Molecular Medicine using diagnostic and therapeutic biomarkers will allow better targeting – higher efficiency Disruption in Pharma industry driving partnerships Convergence: devices and therapy, diagnostics and therapy, computers and biology Application of Biotech breakthroughs to renewable energy Increasing focus on global warming driving new markets for clean technology Nanotechnology enabling miniaturization and automation Breakthroughs in informatics platforms driving and broadening gains in productivity 12
    • Do Entrepreneurs and VC’s mix?
    • Entrepreneurship and Venture Capital Entrepreneurs: Paranoid Optimists 14
    • Entrepreneurship and Venture Capital Entrepreneurs: Paranoid Optimists Venture Investors: Skeptical Optimists 15
    • Entrepreneurship and Venture Capital Entrepreneurs: Paranoid Optimists Venture Capitalists: Skeptical Optimists Early stage venture capital needs to combine both: Paranoid Skeptics? 16
    • Entrepreneurship and Venture Capital Entrepreneurs: Paranoid Optimists Venture Capitalists: Skeptical Optimists Early stage venture capital needs to combine both: Paranoid Skeptics? Cautious optimists! 17